Recently, CD33‐CAR‐NK‐92‐cells have entered clinical trials for relapsed/refractory AML (NCT02944162) and case reports investigated the safety and indicated the encouraging tolerability of these AML‐specific CAR‐NK‐cells.139. The gene discussed is CD33; the disease is acute myeloid leukemia.